Morita Yoshifumi, Kurano Makoto, Sakai Eri, Nishikawa Masako, Sawabe Motoji, Aoki Junken, Yatomi Yutaka
Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan.
Department of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, Japan.
Lipids. 2019 Aug;54(8):487-500. doi: 10.1002/lipd.12175. Epub 2019 Jun 26.
A quantification system for lysophospholipids (lysoPL) was developed, especially for blood samples, using liquid chromatography-tandem mass spectrometry (LC-MS/MS). However, the lysoPL measurement in cerebrospinal fluid (CSF) has not been validated. Therefore, the present study aimed to validate the lysoPL measurement using CSF samples and to elucidate the possible clinical significance of the lysoPL measurement in CSF. For the validation, we observed a good precision and linearity in a sample with high lysoPL levels. The concentrations of lysoPL changed after incubation but the changes were smaller than those observed for serum samples. Moreover, we observed that the CSF levels of 16:0, 18:0 lysophosphatidylcholine, and 18:0, 18:1, and 20:4 lysophosphatidic acid were significantly higher in subjects with central nervous system invasion caused by hematological malignancies or carcinoma than in subjects with no abnormal CSF test results. In conclusion, an LC-MS/MS quantification system for lysoPL in CSF might be useful and could be applied to clinical laboratory testing.
开发了一种用于溶血磷脂（lysoPL）的定量系统，特别是针对血液样本，采用液相色谱-串联质谱法（LC-MS/MS）。然而，脑脊液（CSF）中lysoPL的测量尚未得到验证。因此，本研究旨在验证使用CSF样本进行lysoPL测量，并阐明CSF中lysoPL测量可能的临床意义。为了进行验证，我们在lysoPL水平较高的样本中观察到了良好的精密度和线性。孵育后lysoPL的浓度发生了变化，但变化小于血清样本中观察到的变化。此外，我们观察到，血液系统恶性肿瘤或癌引起中枢神经系统侵犯的受试者中，16:0、18:0溶血磷脂酰胆碱以及18:0、18:1和20:4溶血磷脂酸的CSF水平显著高于CSF检测结果无异常的受试者。总之，用于CSF中lysoPL的LC-MS/MS定量系统可能有用，并可应用于临床实验室检测。
